Skip to main content
Erschienen in: Neurological Sciences 2/2022

17.06.2021 | Original Article

Disability assessment using Google Maps

verfasst von: Luigi Lavorgna, Pietro Iaffaldano, Gianmarco Abbadessa, Roberta Lanzillo, Sabrina Esposito, Domenico Ippolito, Maddalena Sparaco, Simone Cepparulo, Giacomo Lus, Rosa Viterbo, Marinella Clerico, Francesca Trojsi, Paolo Ragonese, Giovanna Borriello, Elisabetta Signoriello, Raffaele Palladino, Marcello Moccia, Francesco Brigo, Maria Troiano, Gioacchino Tedeschi, Simona Bonavita

Erschienen in: Neurological Sciences | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the concordance between Google Maps® application (GM®) and clinical practice measurements of ambulatory function (e.g., Ambulation Score (AS) and respective Expanded Disability Status Scale (EDSS)) in people with multiple sclerosis (pwMS).

Materials and methods

This is a cross-sectional multicenter study. AS and EDSS were calculated using GM® and routine clinical methods; the correspondence between the two methods was assessed. A multinomial logistic model is investigated which demographic (age, sex) and clinical features (e.g., disease subtype, fatigue, depression) might have influenced discrepancies between the two methods.

Results

Two hundred forty-three pwMS were included; discrepancies in AS and in EDDS assessments between GM® and routine clinical methods were found in 81/243 (33.3%) and 74/243 (30.4%) pwMS, respectively. Progressive phenotype (odds ratio [OR] = 2.8; 95% confidence interval [CI] 1.1–7.11, p = 0.03), worse fatigue (OR = 1.03; 95% CI 1.01–1.06, p = 0.01), and more severe depression (OR = 1.1; 95% CI 1.04–1.17, p = 0.002) were associated with discrepancies between GM® and routine clinical scoring.

Conclusion

GM® could easily be used in a real-life clinical setting to calculate the AS and the related EDSS scores. GM® should be considered for validation in further clinical studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chatterji P, Li Y (2021) Effects of the COVID-19 pandemic on outpatient providers in the United States. Med Care 59(1):58–61CrossRef Chatterji P, Li Y (2021) Effects of the COVID-19 pandemic on outpatient providers in the United States. Med Care 59(1):58–61CrossRef
2.
Zurück zum Zitat Moccia M, Lanzillo R, Brescia Morra V et al (2020) Assessing disability and relapses in multiple sclerosis on tele-neurology. Neurol Sci 41:1369–1371CrossRef Moccia M, Lanzillo R, Brescia Morra V et al (2020) Assessing disability and relapses in multiple sclerosis on tele-neurology. Neurol Sci 41:1369–1371CrossRef
3.
Zurück zum Zitat Bombaci A, Abbadessa G, Trojsi F et al (2021) Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci 42(1):9–13CrossRef Bombaci A, Abbadessa G, Trojsi F et al (2021) Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci 42(1):9–13CrossRef
4.
Zurück zum Zitat Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM (2019) Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Mult Scler 25(11):1526–1534CrossRef Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM (2019) Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Mult Scler 25(11):1526–1534CrossRef
5.
Zurück zum Zitat Abbadessa G, Lavorgna L, Miele G et al (2021) Assessment of multiple sclerosis disability progression using a wearable biosensor: a pilot study. J Clin Med 10(6):1160CrossRef Abbadessa G, Lavorgna L, Miele G et al (2021) Assessment of multiple sclerosis disability progression using a wearable biosensor: a pilot study. J Clin Med 10(6):1160CrossRef
6.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRef Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRef
7.
Zurück zum Zitat Kruidenier LM, Nicolai SPA, Willidgendael EM et al (2009) Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients intermittent claudication. BMC Cardiovasc Disord 2(9):9CrossRef Kruidenier LM, Nicolai SPA, Willidgendael EM et al (2009) Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients intermittent claudication. BMC Cardiovasc Disord 2(9):9CrossRef
8.
Zurück zum Zitat Sharrack B, Hughes RCA (1997) Reliability of distance estimation by doctors and patients: cross sectional study. BMJ 315:1652–1654CrossRef Sharrack B, Hughes RCA (1997) Reliability of distance estimation by doctors and patients: cross sectional study. BMJ 315:1652–1654CrossRef
9.
Zurück zum Zitat Hohart J, Lamping D, Fitzpatrick R et al (2001) The multiple sclerosis impact scale: a new patients based outcome measures. Brain 124:962–973CrossRef Hohart J, Lamping D, Fitzpatrick R et al (2001) The multiple sclerosis impact scale: a new patients based outcome measures. Brain 124:962–973CrossRef
10.
Zurück zum Zitat PiriÇinar B, GüvenYorgun K (2018) What we learned from the history of multiple sclerosis measurement: expanded disability status scale. Arch Neuropsychiatry 55(Supplement 1):69–75 PiriÇinar B, GüvenYorgun K (2018) What we learned from the history of multiple sclerosis measurement: expanded disability status scale. Arch Neuropsychiatry 55(Supplement 1):69–75
11.
Zurück zum Zitat Sparaco M, Lavorgna L, Conforti R et al (2018) The role of wearable devices in multiple sclerosis. Mult Scler Int 2018:7627643PubMedPubMedCentral Sparaco M, Lavorgna L, Conforti R et al (2018) The role of wearable devices in multiple sclerosis. Mult Scler Int 2018:7627643PubMedPubMedCentral
12.
Zurück zum Zitat Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRef Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRef
13.
Zurück zum Zitat Hind D, Kaklamanou D, Beever D et al (2016) The assessment of depression in people with multiple sclerosis: a systematic review of psychometric validation studies. BMC Psychiatry 16:278CrossRef Hind D, Kaklamanou D, Beever D et al (2016) The assessment of depression in people with multiple sclerosis: a systematic review of psychometric validation studies. BMC Psychiatry 16:278CrossRef
14.
Zurück zum Zitat Goldman MD, Motl RW, Rudick RA (2010) Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord 3:229–239CrossRef Goldman MD, Motl RW, Rudick RA (2010) Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord 3:229–239CrossRef
15.
Zurück zum Zitat Confavreux C, Vukusic S, Adeline P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782CrossRef Confavreux C, Vukusic S, Adeline P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782CrossRef
16.
Zurück zum Zitat Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Eng J Med 343:1430–1438CrossRef Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Eng J Med 343:1430–1438CrossRef
17.
Zurück zum Zitat Kimmelman J, Mogil JS, Dirnagl U (2014) Distinguishing between exploratory and confirmatory preclinical research will improve translation. Plos Biol 12(5):e1001863CrossRef Kimmelman J, Mogil JS, Dirnagl U (2014) Distinguishing between exploratory and confirmatory preclinical research will improve translation. Plos Biol 12(5):e1001863CrossRef
18.
Zurück zum Zitat Arain M, Campbell MJ, Cooper CL, Lancaster GA (2010) What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 10:67CrossRef Arain M, Campbell MJ, Cooper CL, Lancaster GA (2010) What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 10:67CrossRef
19.
Zurück zum Zitat Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155–163CrossRef Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155–163CrossRef
20.
Zurück zum Zitat Mukaka MM (2012) A guide to appropriate use of Correlation coefficient in medical research MM Mukaka. Malawi Med J 24(3):69–71PubMedPubMedCentral Mukaka MM (2012) A guide to appropriate use of Correlation coefficient in medical research MM Mukaka. Malawi Med J 24(3):69–71PubMedPubMedCentral
21.
Zurück zum Zitat Mandrekar JN (2011) Measures of interrater agreement. J Thorac Oncol 6(1):6–7CrossRef Mandrekar JN (2011) Measures of interrater agreement. J Thorac Oncol 6(1):6–7CrossRef
23.
Zurück zum Zitat Herbolsheimer F, Riepe M, Peter R (2018) Cognitive function and the agreement between self-reported and accelerometer-accessed physical activity. BMC Geriatr 18:56CrossRef Herbolsheimer F, Riepe M, Peter R (2018) Cognitive function and the agreement between self-reported and accelerometer-accessed physical activity. BMC Geriatr 18:56CrossRef
24.
Zurück zum Zitat Kalron A, Aloni R (2018) Contrasting relationship between depression, quantitative gait characteristics and self-report walking difficulties in people with multiple sclerosis. Mult Scler Relat Disord 19:1–5CrossRef Kalron A, Aloni R (2018) Contrasting relationship between depression, quantitative gait characteristics and self-report walking difficulties in people with multiple sclerosis. Mult Scler Relat Disord 19:1–5CrossRef
25.
Zurück zum Zitat Dalgas U, Langeskov-Christensen M, Skjerbæk AG (2018) Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study. J Neurol Sci 387:179–186CrossRef Dalgas U, Langeskov-Christensen M, Skjerbæk AG (2018) Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study. J Neurol Sci 387:179–186CrossRef
26.
Zurück zum Zitat Berger W, Payne MWC, Morrow SA (2017) Self reported maximum walking distance in persons with MS may affect the EDSS. Neurol Sci 379:77–80CrossRef Berger W, Payne MWC, Morrow SA (2017) Self reported maximum walking distance in persons with MS may affect the EDSS. Neurol Sci 379:77–80CrossRef
27.
Zurück zum Zitat Neil BA, Kenneth EG, Darryl GT et al (2000) Self-Reported walking ability predicts functional mobility performance in frail older adults. JAGS 48:1408–1413CrossRef Neil BA, Kenneth EG, Darryl GT et al (2000) Self-Reported walking ability predicts functional mobility performance in frail older adults. JAGS 48:1408–1413CrossRef
28.
Zurück zum Zitat Giantomaso T, Makowsky L, Ashworth N et al (2003) The validity of patient and physician estimate of walking distance. Clin Rehabil 17:394–401CrossRef Giantomaso T, Makowsky L, Ashworth N et al (2003) The validity of patient and physician estimate of walking distance. Clin Rehabil 17:394–401CrossRef
29.
Zurück zum Zitat Minden SL, Frankel D, Hadden L et al (2004) Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka longitudinal multiple sclerosis study. Neurorehabilitation 19(1):55–67CrossRef Minden SL, Frankel D, Hadden L et al (2004) Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka longitudinal multiple sclerosis study. Neurorehabilitation 19(1):55–67CrossRef
30.
Zurück zum Zitat Skjerbæk AG, Boesen F, Petersen T, Rasmussen PV, Stenager E, Nørgaard M, Feys P, Kjeldgaard-Jørgensen ML, Hvid LG, Dalgas U. (2019) Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study. Mult Scler. 25(12):1653-1660. https://doi.org/10.1177/1352458518795416CrossRefPubMed Skjerbæk AG, Boesen F, Petersen T, Rasmussen PV, Stenager E, Nørgaard M, Feys P, Kjeldgaard-Jørgensen ML, Hvid LG, Dalgas U. (2019) Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study. Mult Scler. 25(12):1653-1660.  https://​doi.​org/​10.​1177/​1352458518795416​CrossRefPubMed
Metadaten
Titel
Disability assessment using Google Maps
verfasst von
Luigi Lavorgna
Pietro Iaffaldano
Gianmarco Abbadessa
Roberta Lanzillo
Sabrina Esposito
Domenico Ippolito
Maddalena Sparaco
Simone Cepparulo
Giacomo Lus
Rosa Viterbo
Marinella Clerico
Francesca Trojsi
Paolo Ragonese
Giovanna Borriello
Elisabetta Signoriello
Raffaele Palladino
Marcello Moccia
Francesco Brigo
Maria Troiano
Gioacchino Tedeschi
Simona Bonavita
Publikationsdatum
17.06.2021
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 2/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05389-7

Weitere Artikel der Ausgabe 2/2022

Neurological Sciences 2/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.